RxDoctor Payments Data

Michael Freeman, MD

Gastroenterology · Cape Girardeau, MONPI 1851361455

Payments from drug & device makers

$5,490in general payments, 2019–2025

Across 310 payments — averaging $17.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$725
  • Johnson & Johnson$571
  • Bristol Myers Squibb$372
  • UCB, Inc.$233
  • Pfizer$173
  • plus $973 from 22 others

What the payments were for

  • Food & beverage$5,39198%
  • Education$992%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,490 in reported general payments places this provider in the 65th percentile of 374 gastroenterology providers in Missouri.

See all gastroenterology providers in Missouri

Medicare billing

Part B allowed, 2024
$178,034
Medicare patients
658
Services billed
1,419

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab22$581,730
Humira(Cf) PenAdalimumab30$338,707
Skyrizi On-BodyRisankizumab-Rzaa13$266,453
EntyvioVedolizumab27$229,479
CreonLipase/Protease/Amylase17$55,080
LinzessLinaclotide55$34,599
MovantikNaloxegol Oxalate18$6,885
Colestipol Hcl66$6,484
Colesevelam Hcl39$4,018
Dexlansoprazole DrDexlansoprazole16$3,528
Pantoprazole Sodium283$3,454
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine41$1,306
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates15$951
Omeprazole102$737
Nadolol11$711

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$571$581,73022 claims
Takeda Pharmaceuticals U.S.A., Inc.Entyvio$725$229,47927 claims
AbbVieCreon, Linzess$2,443$89,67872 claims
Redhill Biopharma Inc.Movantik$11$6,88518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 374 gastroenterology providers in Missouri.

Other gastroenterology in Cape Girardeau

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →